TransCode Therapeutics filed a Second Amended and Restated Certificate of Designation for its Series A and Series B Non-Voting Convertible Preferred Stock on August 3, 2026. This amendment removed the requirement for 60 days' notice to change or waive the beneficial ownership limitation previously set in the October 2025 designation. No additional securities were issued or sold in connection with this filing. TransCode Therapeutics operates in the biotechnology industry, focusing on developing therapies for rare diseases.
